Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NodThera logo — Treating chronic disease by targeting inflammation at its so...

NodThera

Treating chronic disease by targeting inflammation at its source

Founded 2016 United States Philadelphia, United States 22 employees Series B Total: $77.08M Biotechnology, Health Care +1

General Information

Company Name NodThera
Founded Year 2016
Location United States Philadelphia, United States
Employees 22
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series B
Business Model B2B, B2B2C
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with NodThera. To contact NodThera, visit nodthera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NodThera compare?

A PDF of NodThera and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NodThera soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NodThera

NodThera, founded in 2016, is carving a niche within the Biotechnology, Health Care, and Life Sciences sectors. The company's groundbreaking work focuses on developing a novel class of potent and highly selective NLRP3 inflammasome inhibitors, potentially revolutionizing the treatment of chronic inflammation-driven diseases.

Operating from offices in Cambridge, UK and Boston, MA, NodThera prides itself on a diverse and dynamic team driven by shared ambition and innovation. The slogan "Treating chronic disease by targeting inflammation at its source" encapsulates their mission.

The company received a significant financial boost with a $55.00M Series B investment on 03 June 2020. This round was backed by noteworthy investors including F-Prime Capital, Sofinnova Partners, 5AM Ventures, Cowen Digital, Epidarex Capital, Sanofi Ventures, and Novo Ventures, indicating strong confidence in NodThera's innovative potential and future trajectory.

Business keywords: biotech, inflammasome research, chronic inflammation treatment, NLRP3 inhibitors, neuroinflammatory diseases, immunotherapy, drug development, innate immune system, Cambridge, Seattle, Boston, UK, USA, pharmaceuticals

Services & Products

Development of NLRP3 inhibitors
Clinical research and trials
Pharmaceutical innovation

Target Customers

Individuals with age-related diseases Patients with cardiometabolic disorders Patients with neuroinflammatory conditions Healthcare providers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B Undisclosed -
01 Oct 2021
Series B £44.60M 7
F-Prime Capital Sofinnova Partners 5AM Ventures
F-Prime Capital, Sofinnova Partners +5
01 Jun 2020
Series A €32.00M 4
F-Prime Capital Sofinnova Partners 5AM Ventures
F-Prime Capital, Sofinnova Partners +2
01 Jun 2018
Early VC $480.00K -
01 Dec 2017

NodThera Alternatives & Competitors

View All Alternatives
NodThera vs
Azome Therapeutics
Azome Therapeutics

Developing selective NLRP3 inflammasome inhibitors for severe inflammatory diseases

Seed
3 employees
Biopharma, Biotechnology
NodThera vs
Upstream Bio
Upstream Bio United States

Developing treatments for inflammatory diseases

IPO
78 employees
Biotechnology, Health Care
NodThera vs
BIORCHESTRA Co., Ltd.
BIORCHESTRA Co., Ltd. United States

We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift for neurod...

Series C
16 employees
Biopharma, Biotechnology
View all alternatives

FAQ About NodThera

Treating chronic disease by targeting inflammation at its source
NodThera was founded in 2016.
NodThera is headquartered in Philadelphia, United States.
NodThera operates in Biotechnology, Health Care and Life Sciences. Its work centres on biotech, inflammasome research, chronic inflammation treatment and NLRP3 inhibitors. Its customers include Individuals with age-related diseases, Patients with cardiometabolic disorders and Patients with neuroinflammatory conditions.
NodThera has a B2B and B2B2C business model. Its revenue comes from Product Sales and Licensing.
NodThera has approximately 22 employees.
NodThera has completed 4 funding rounds, raising a total of $77.08M. The latest funding stage is Series B.
NodThera offers: Development of NLRP3 inhibitors, Clinical research and trials, Pharmaceutical innovation.
Top alternatives and competitors to NodThera include Azome Therapeutics, Upstream Bio, BIORCHESTRA Co., Ltd., Inflazome, Invirsa, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NodThera and Azome Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NodThera, https://bouncewatch.com/company/nodthera, updated 21 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout